论文部分内容阅读
近来发现并证实,应用抗心律失常药物可并发室性心律失常加重。本文为回顾性研究,旨在论证与此并发症有关的临床参数。研究的药物选自膜活性抗心律失常药中的3个亚类,即奎尼丁、美西律、英卡胺。方法:查阅500份室性心律失常患者曾用抗心律失常药作试验治疗的病历,其中不含急性发病的心律失常如急性心肌梗塞或低钾血症。从中选择47例病人进行分析,每例均选2名未发生心律失常加重者作对照。这47例病人共发生心律失常加重发作51次,4例病人在用第二种药时也发生心律失常加重。病人入院后停用抗心律失常药,经4个半衰期以上的清除期后,通过动态心电图和症状限制性平板运动试验作基础评价,然后进行创伤性或非创伤性药物
Recently found and confirmed that the application of anti-arrhythmic drugs can be complicated by increased ventricular arrhythmias. This article is a retrospective study to demonstrate the clinical parameters associated with this complication. The drugs studied were selected from the three subgroups of membrane active antiarrhythmic drugs, quinidine, mexiletine, and inflixamine. METHODS: The medical records of 500 patients with ventricular arrhythmias who had been treated with anti-arrhythmic drugs were reviewed and did not include acute-onset arrhythmias such as acute myocardial infarction or hypokalemia. 47 patients were selected for analysis, each case were selected 2 without arrhythmia exacerbation as a control. The 47 patients had a total of 51 episodes of arrhythmia, and 4 patients had arrhythmias worse with the second drug. Patients were discontinued after admission of anti-arrhythmic drugs, after more than four half-lives of clearance, by dynamic electrocardiogram and symptom? My limit treadmill exercise test as a basis for evaluation, and then traumatic or non-traumatic drugs